Current Epidemiological Status and Antibiotic Resistance Profile of Urinary Tract Infection
With a longitudinal (2020–2021) completion, a set of 300 urine samples of individuals suspected of UTI was characterized based on the biochemical analysis and Kirby Bauer's disc diffusion method. Throughout, a total of 167 samples revealed UTI positivity by obtaining bacterial growth. Reporting that E. coli (69.4 %) was the most dominant when compared with Klebsiella (14.3 %), Proteus (5.9 %), S. aureus (4.7 %), P. aeruginosa (3.5 %), and Enterobacter (1.7 %), respectively. Gender-wise discrimination showed that E. coli was highly distributed among female (50.2 %) patients. A prominent percentage of E. coli (41.9 %) was found in the age group between 21-40 years. Isolates of E. coli represented the highest degree of resistance to Amoxicillin and Ceftriaxone (85.3 %), while highly sensitive to Amikacin, and Tazobactam (94.8 %). S. aureus was found highly resistant to Amoxicillin, Levofloxacin, Sulbactam, and Doxycycline (75 %), while highly sensitive to Meropenem, and Cefotaxime (100 %). Proteus spp. was found highly resistant to Sulbactam, and Cefotaxime (100 %), while highly sensitive to Tazobactam (100 %). Enterobacter was found highly resistant to Gentamicin (100 %), while highly sensitive to Aztreonam (100 %). Klebsiella was found highly resistant to Levofloxacin, and Doxycycline (91.6 %), while highly sensitive to Amikacin, Tazobactam, Gentamicin, and Cefoxitin (75 %). P. aeruginosa was found highly resistant to Nalidixic acid (100 %), while highly sensitive to Meropenem, Ceftriaxone, Gentamicin, and Cefotaxime. In conclusion, the Amikacin and Tazobactam were seen to be effective for empirical therapy of UTI.
Received: Nov 09, 2021; Accepted: Jan 14, 2022; Published: March 24, 2022
Shah, S. H.,
Jan, S. A.,
& Qazi, I.
Current Epidemiological Status and Antibiotic Resistance Profile of Urinary Tract Infection,
Journal of Bioresource Management, 9